Overview:
According to Cleveland Clinic, venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a common, lethal disorder that affects hospitalized and non-hospitalized patients, recurs frequently, is often overlooked, and results in long-term complications including chronic thromboembolic pulmonary hypertension (CTPH) and the post-thrombotic syndrome (PTS). An inclusive scientific review by the WTD steering committee revealed that 10 million cases of VTE occur annually – across low, middle and high income countries. In addition up to 60% of VTE cases occur during or after hospitalization, making it a leading preventable cause of hospital death. Venous thromboembolism treatment market can be segmented on the basis of type of disease such as deep venous thrombosis (DVT) and pulmonary embolism (PE). On the basis of drugs, venous thromboembolism treatment market is segmented as heparin, apixaban, dabigatran, rivaroxaban, edaxaban, and warfarin. The therapy market of VTE treatment comprises compression therapy and thrombolytic therapy.
The key drivers assisting the overall market growth of venous thromboembolism treatment are increasing prevalence and incidence rate of venous thromboembolism and high awareness related to existing treatments for venous thromboembolism are driving the global venous thromboembolism treatment market. In addition factors such as stringent regulatory approvals and challenges in adaption of newer drugs and therapies in the market are restraining the growth of this market. North America is the leading regional market for venous thromboembolism treatments and is trailed by Europe due to the existence of a large number of population suffering with venous thromboembolic in these regions. The key factors driving North America and Europe venous thromboembolism market are high healthcare expenditure, developed healthcare infrastructure and high awareness related to the disease and available treatments.
The global venous thromboembolism treatment market is segmented on the following bases:
1. Type of Disease
a. Deep Venous Thrombosis
b. Pulmonary Embolism
2. Type of Treatment
a. Therapeutics
i. Heparin
ii. Apixaban
iii. Dabigatran
iv. Rivaroxaban
v. Edaxaban
vi. Warfarin
b. Other Treatments
i. Compression Therapy
ii. Inferior Vena Cava Filter
iii. Thrombolytic Therapy
3. Geography
a. North America
i. US
ii. Canada
b. Europe
i. UK
ii. Germany
iii. Rest of Europe
c. Asia-Pacific
i. Japan
ii. China
iii. Rest of APAC
d. Latin America
e. Middle East and Africa
Key Players Identified for Venous Thromboembolism Treatment Market Include but are Not Limited to:
Abbott Laboratories, Merck & Co., Sanofi S.A., Dupont Pharm Co, Boehringer Ingelheim GmbH, Upsher-Smith Laboratories,Inc., Wockhardt Ltd, Bayer AG, Bristol-Myers Squibb Company, 3M Health Care, ArjoHuntleigh, BSN medical, Medtronic plc, Bio Compression Systems, Inc., and Pfizer Inc. and others.
This report offers:
- An overview of the global markets for venous thromboembolism treatment
- Market trends assessment for the period 2014-2022, with historical information for 2014 & 2015, and projections through 2022, with respective CAGRS during 2016-2022
- Qualitative assessment tools such as market drivers, challenges and opportunities
- Market competition scrutiny tools such as market share analysis, fractal map assessment, Porter’s Five Forces model
- Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics.
- A general overview of the industry structure
- Company profiles highlighting key information about the major players operating in the venous thromboembolism treatment market
